Abstract
Several studies, including genome wide association studies (GWAS), have strongly sug-gested a central role for the ATP-binding cassette transporter subfamily A member 7 (ABCA7) in Alzheimer’s disease (AD). This ABC transporter is now considered as an important genetic deter-minant for late onset Alzheimer disease (LOAD) by regulating several molecular processes such as cholesterol metabolism and amyloid processing and clearance. In this review we shed light on these new functions and their cross-talk, explaining its implication in brain functioning, and therefore in AD onset and development.
| Original language | English |
|---|---|
| Article number | 4603 |
| Journal | International Journal of Molecular Sciences |
| Volume | 22 |
| Issue number | 9 |
| ISSN | 1661-6596 |
| DOIs | |
| Publication status | Published - 27.04.2021 |
Funding
Funding: S.D. has received fellowships from the Region Hauts-de-France and the University of Artois. F.G. has been supported by internal grants from University of Artois (BQR-ABCA7), from foundation France Alzheimer et Maladies apparentées (AAP 2013, #22) and under the ERANET JPcofuND 2-NET-PETABC collaborative project by grants from the French national agency (ANR, grant number ANR-20-JPW2-0002-04). The work of J.P. was supported by the following grants: Deutsche Forschungsgemeinschaft/Germany (DFG 263024513); Ministerium für Wirtschaft und Wissenschaft Sachsen-Anhalt/Germany (ZS/2016/05/78617); Latvian Council of Science/Latvia (lzp-2018/1-0275); Nasjonalforeningen (16154 to Luisa Möhle), HelseSØ/Norway (2019054, 2019055); Barnekreftforeningen (19008); EEA grant/Norges grants (TACˇ R TARIMAD TO100078); Norges forskningsrådet/Norway (260786 PROP-AD, 295910 NAPI, 327571 PETABC). PROP-AD and PETABC are EU Joint Programme-Neurodegenerative Disease Research (JPND) projects. PROP-AD is supported through the following funding organizations under the aegis of JPND—www.jpnd.eu (accessed on 31 December 2020) (AKA #301228—Finland, BMBF #01ED1605—Germany, CSO-MOH #30000-12631—Israel, NFR #260786—Norway, SRC #2015-06795—Sweden). PETABC is supported through the following funding organisations under the aegis of JPND—www.jpnd.eu (NFR #32757— Norway, FFG #882717—Austria, BMBF #XXXXX—Germany, MSMT #8F21002—Czech Republic, VIAA #ES RTD/2020/26—Latvia, ANR #20-JPW2-0002-04—France, SRC #2020-02905—Sweden). The projects receive funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement #643417 (JPco-fuND). S.D. has received fellowships from the Region Hauts-de-France and the University of Artois. F.G. has been supported by internal grants from University of Artois (BQR-ABCA7), from foundation France Alzheimer et Maladies apparent?es (AAP 2013, #22) and under the ERANET JPcofuND 2-NET-PETABC collaborative project by grants from the French national agency (ANR, grant number ANR-20-JPW2-0002-04). The work of J.P. was supported by the following grants: Deutsche Forschungsgemeinschaft/Germany (DFG 263024513); Ministerium f?r Wirtschaft und Wissenschaft Sachsen-Anhalt/Germany (ZS/2016/05/78617); Latvian Council of Science/Latvia (lzp-2018/1-0275); Nasjonalforeningen (16154 to Luisa M?hle), HelseS?/Norway (2019054, 2019055); Barnekreftforeningen (19008); EEA grant/Norges grants (TA?R TARIMAD TO100078); Norges forskningsr?det/Norway (260786 PROP-AD, 295910 NAPI, 327571 PETABC). PROP-AD and PETABC are EU Joint Programme-Neurodegenerative Disease Research (JPND) projects. PROP-AD is supported through the following funding organizations under the aegis of JPND?www.jpnd.eu (ac-cessed on 31 December 2020) (AKA #301228?Finland, BMBF #01ED1605?Germany, CSO-MOH #30000-12631?Israel, NFR #260786?Norway, SRC #2015-06795?Sweden). PETABC is supported through the following funding organisations under the aegis of JPND?www.jpnd.eu (NFR #32757? Norway, FFG #882717?Austria, BMBF #XXXXX?Germany, MSMT #8F21002?Czech Republic, VIAA #ES RTD/2020/26?Latvia, ANR #20-JPW2-0002-04?France, SRC #2020-02905?Sweden). The projects receive funding from the European Union?s Horizon 2020 research and innovation programme under grant agreement #643417 (JPco-fuND).
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)
